Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 5;8(11):1988–1994. doi: 10.7150/jca.18900

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Kaplan-Meier curves of progression-free survival (A) and overall survival (B). (A) The median progression-free survival time was prolonged in the vitamin K-dosed group (n=29) compared with the sorafenib alone group (n=36) (6.0 months, 95% CI 3.7-8.3 months vs. 2.0 months, 95% CI 1.4-2.6 months; P<0.001 by log-rank test), and the hazard ratio was 0.25 (95% CI 0.14-0.46). (B) The median overall survival time was also significantly extended (12.5 months, 95% CI 5.4-19.6 months vs. 10.0 months, 95% CI 5.9-14.1 months; P = 0.009), and the hazard ratio was 0.47 (95% CI 0.26-0.85).